Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K
Cancer02:18

Cancer

55.4K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
55.4K
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

7.3K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
7.3K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

6.3K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
6.3K
The Tumor Microenvironment02:17

The Tumor Microenvironment

3.0K
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatial transcriptomics reveals compartment-specific cytotoxic T cell crosstalk with AT2 and goblet cells in advanced COPD.

Biomarker research·2026
Same author

Cutaneous <i>Mycobacterium chelonae</i> Infection During Ibrutinib Treatment in Chronic Lymphocytic Leukemia: A Case Report.

Microorganisms·2026
Same author

Special Issue "Resistance to Therapy in Ovarian Cancers".

International journal of molecular sciences·2026
Same author

Borreliosis and Other Tick-Borne Diseases in the Northern and Southern Hemispheres.

Microorganisms·2025
Same author

Deletion of MMP12 improves energy metabolism and brown adipose tissue function in mice prone to cardiometabolic disease.

Journal of lipid research·2025
Same author

CRISPR/Cas Tools for the Detection of <i>Borrelia</i> sensu lato in Human Samples.

Genes·2025

Related Experiment Video

Updated: Mar 17, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K

Tumour heterogeneity: principles and practical consequences.

Giorgio Stanta1, Stephan Wenzel Jahn2, Serena Bonin3

  • 1Department of Medical Sciences, University of Trieste, Strada di Fiume 447, Trieste, 34149, Italy. stanta@icgeb.org.

Virchows Archiv : an International Journal of Pathology
|July 15, 2016
PubMed
Summary

Tumour heterogeneity drives therapy resistance and impacts cancer research reproducibility. Understanding this complexity, including clonal and non-clonal variations, is crucial for developing new diagnostic tools and targeted therapies.

Keywords:
ClonalEpigeneticFunctional plasticityIntertumourIntratumourMolecularPhenotypicSpatialTemporalTumour heterogeneity

More Related Videos

Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.3K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.3K
Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

1.4K

Area of Science:

  • Oncology
  • Cancer Research
  • Pathology

Background:

  • Tumour heterogeneity is a key factor in acquired therapy resistance.
  • It also contributes to the lack of reproducibility in clinical cancer research.
  • Understanding heterogeneity is vital for advancing cancer treatment and research.

Purpose of the Study:

  • To review the phenomenon of tumour heterogeneity within primary tumours and between primary tumours and metastases.
  • To discuss current knowledge and future developments in studying tumour heterogeneity.
  • To explore potential similarities across major tumour types for new targeted therapy strategies.

Main Methods:

  • Review of existing literature on tumour heterogeneity.
  • Discussion of different levels and types of heterogeneity (clonal and non-clonal).
  • Exploration of established and emerging in situ methods and biomarkers.

Main Results:

  • Tumour heterogeneity presents challenges in therapy and research reproducibility.
  • New tools and biomarkers are needed to effectively study heterogeneity.
  • Both clonal and non-clonal phenotypic heterogeneity are important considerations.

Conclusions:

  • Addressing tumour heterogeneity is essential for improving cancer treatment outcomes.
  • Development of novel diagnostic and therapeutic strategies is required.
  • Further research into heterogeneity across diverse cancer types may reveal new therapeutic avenues.